news
Global health funding shift impacts hepatitis elimination efforts
A deep dive in The Lancet Global Health reveals how global health funding is pivoting from disease-specific programs to integrated primary care models. This shift, particularly for hepatitis, means leveraging existing HIV platforms to manage costs, which could impact future elimination targets. It's a reminder of what happens when the money moves.
A deep dive in The Lancet Global Health reveals how global health funding is pivoting from disease-specific programs to integrated primary care models. This shift, particularly for hepatitis, means leveraging existing HIV platforms to manage costs, which could impact future elimination targets. It's a reminder of what happens when the money moves.
The architecture take
This bit in The Lancet is a pretty clear signal: the big global health money is drying up for single-disease fights like hepatitis. Instead, they're funneling it into 'integrated primary care,' which sounds great on paper but really means shoehorning new issues onto old platforms, like tacking hepatitis onto HIV programs. It's a cost-saving move, pure and simple, supposedly to keep past investment gains from totally vanishing. But when you spread resources thinner, something usually gives. You should watch how this plays out for actual disease elimination and what it means for vulnerable populations. The grand idea of wiping out diseases doesn't just happen because everyone agrees it's good; it needs dedicated cash, and that's getting scarcer. It's not about what works, it's about what's affordable.